Giotrif®

For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum based chemotherapy.

Indications Non-small cell lung cancer (NSCLC)
Brand Names Giotrif®
Gilotrif®
Active ingredients afatinib
Packshot Giotrif<sup>®</sup>

 

More related content

  • Giotrif®

Oncology

Giotrif® for distinct types of EGFR m+ NSCLC

Read moreon

Giotrif® for distinct types of EGFR m+ NSCLC